ATE391778T1 - Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen - Google Patents

Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen

Info

Publication number
ATE391778T1
ATE391778T1 AT98904842T AT98904842T ATE391778T1 AT E391778 T1 ATE391778 T1 AT E391778T1 AT 98904842 T AT98904842 T AT 98904842T AT 98904842 T AT98904842 T AT 98904842T AT E391778 T1 ATE391778 T1 AT E391778T1
Authority
AT
Austria
Prior art keywords
vegf
mutants
growth factor
vascular endothelial
endothelial cell
Prior art date
Application number
AT98904842T
Other languages
English (en)
Inventor
Kari Alitalo
Vladimir Joukov
Original Assignee
Ludwig Inst Cancer Res
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Licentia Ltd filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE391778T1 publication Critical patent/ATE391778T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98904842T 1997-02-05 1998-02-02 Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen ATE391778T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/795,430 US6130071A (en) 1997-02-05 1997-02-05 Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof

Publications (1)

Publication Number Publication Date
ATE391778T1 true ATE391778T1 (de) 2008-04-15

Family

ID=25165495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904842T ATE391778T1 (de) 1997-02-05 1998-02-02 Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen

Country Status (7)

Country Link
US (1) US6130071A (de)
EP (1) EP0972028B1 (de)
JP (1) JP4524340B2 (de)
AT (1) ATE391778T1 (de)
AU (1) AU748369C (de)
CA (1) CA2279554C (de)
DE (1) DE69839340T2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
ATE309360T1 (de) 1994-03-08 2005-11-15 Human Genome Sciences Inc Vaskularer endothelialer wachstumsfaktor 2
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US7423125B2 (en) * 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
DK0848755T4 (da) * 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
WO2000058511A1 (en) * 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
US6764820B2 (en) * 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
DE60131146T2 (de) * 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
NZ518077A (en) * 2000-08-04 2003-11-28 Human Genome Sciences Inc Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
AU2002224471A1 (en) * 2000-11-01 2002-05-15 Aventis Pharma S.A. In vivo stimulation of angiogenic activity
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7026462B2 (en) * 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CA2435503C (en) * 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US20030170786A1 (en) * 2001-04-13 2003-09-11 Rosen Craig A. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
WO2002083849A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
WO2002083704A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
JP2005500045A (ja) * 2001-07-12 2005-01-06 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管内皮細胞材料および方法
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP1587944A4 (de) 2002-03-01 2007-03-21 Dyax Corp Kdr und vegf/kdr-bindende peptide und ihre diagnostische und therapeutische veranwendung bei der diagnose und therapie
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20030232437A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-C expression
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
EP1635860A2 (de) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Verwendung von vegf-c oder vegf-d in der wiederherstellende chirurgie
US20050032697A1 (en) * 2003-06-12 2005-02-10 Kari Alitalo Heparin binding VEGFR-3 ligands
US6990436B1 (en) * 2003-11-28 2006-01-24 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Computing frequency by using generalized zero-crossing applied to intrinsic mode functions
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
WO2006025940A2 (en) * 2004-06-30 2006-03-09 University Of Rochester Photodynamic therapy with spatially resolved dual spectroscopic monitoring
JP4988606B2 (ja) 2005-02-28 2012-08-01 サンガモ バイオサイエンシズ インコーポレイテッド 抗血管新生方法及び組成物
ATE502956T1 (de) 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US20070282404A1 (en) * 2006-04-10 2007-12-06 University Of Rochester Side-firing linear optic array for interstitial optical therapy and monitoring using compact helical geometry
WO2008080052A1 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Transgenic mice expressing humanized vegf
US20080267924A1 (en) * 2007-02-07 2008-10-30 Vegenics Limited Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
US20100331927A1 (en) * 2007-05-02 2010-12-30 Cottrell William J Feedback-controlled method for delivering photodynamic therapy and related instrumentation
US8107710B2 (en) 2008-05-23 2012-01-31 University Of Rochester Automated placental measurement
WO2010009412A2 (en) 2008-07-18 2010-01-21 University Of Rochester Medical Center Low-cost device for c-scan photoacoustic imaging
WO2010045421A2 (en) * 2008-10-15 2010-04-22 University Of Rochester Photoacoustic imaging using a versatile acoustic lens
WO2010102215A2 (en) * 2009-03-06 2010-09-10 University Of Rochester Automated placental measurement
US20110081056A1 (en) * 2009-10-05 2011-04-07 Salafia Carolyn M Automated placental measurement
PT2956476T (pt) 2013-02-18 2020-02-21 Vegenics Pty Ltd Moléculas de ligação e usos destas
EP4121106A1 (de) * 2020-03-20 2023-01-25 Centre National de la Recherche Scientifique (CNRS) Neue anti-vegfc-antikörper und verwendungen davon

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
DE69034135T3 (de) * 1989-12-22 2012-08-23 Laboratoires Serono S.A. DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
CA2064331C (en) * 1991-03-28 2003-02-18 Marvin L. Bayne Vascular endothelial cell growth factor c subunit
CA2092695A1 (en) * 1991-05-15 1992-11-16 Oliver Smithies Genomic modifications with homologous dna targeting
US5326695A (en) * 1992-05-15 1994-07-05 Ludwig Institute For Cancer Research Platelet derived growth factor agonists
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5932540A (en) * 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
ATE309360T1 (de) * 1994-03-08 2005-11-15 Human Genome Sciences Inc Vaskularer endothelialer wachstumsfaktor 2
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
ATE326484T1 (de) * 1994-06-09 2006-06-15 Licensing Oy Monoklonaler antikörper gegen flt4-rezeptor- tyrosinkinase und dessen verwendung zur diagnose und therapie
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
WO1996039421A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3
DK0848755T4 (da) * 1995-09-08 2011-05-23 Genentech Inc VEGF relateret protein
WO1997017442A1 (en) * 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein

Also Published As

Publication number Publication date
CA2279554A1 (en) 1998-08-06
JP2001523951A (ja) 2001-11-27
CA2279554C (en) 2012-09-18
AU6262498A (en) 1998-08-25
AU748369B2 (en) 2002-06-06
US6130071A (en) 2000-10-10
EP0972028B1 (de) 2008-04-09
DE69839340D1 (de) 2008-05-21
DE69839340T2 (de) 2009-04-09
AU748369C (en) 2003-03-20
JP4524340B2 (ja) 2010-08-18
EP0972028A1 (de) 2000-01-19

Similar Documents

Publication Publication Date Title
ATE391778T1 (de) Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen
DE69739469D1 (de) Rekombinanter vasculärer Endothelzellen Wachstumsfaktor D (VEGF-D)
ATE352618T1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
MX9100052A (es) Biblioteca(o conjunto)de bio-oligomeros al azar,un metodo de sintesis de los mismos y un metodo de uso de los mismos
NO20040154L (no) Farmasoytisk blanding omfattende human-antistoffer som binder TNF<alfa>, samt anvendelser derav
DE69834027D1 (de) Tumor-nekrose-faktor rezeptor 5
DK0914345T3 (da) Antistoffer, som binder til monocyt-kemoattraktant-protein-1-receptor (MCP-1-receptor) (CCR2)
ATE365796T1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
NO973933D0 (no) Vaskulær endotelvekstfaktor B
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
DK1012274T4 (da) Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
DE69535641D1 (de) Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
ATE259377T1 (de) An den zelloberflächenrezeptor hek bindendes cytokin
ATE368682T1 (de) Als 2f1 bezeichnetes rezeptorprotein
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
DK1009817T3 (da) RTD-receptor
EP0990703A4 (de) Neues polypeptid, dafür kodierende dna und deren verwendungen
DE69734596D1 (de) "smoothened" proteine aus wirbeltieren
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
AR010333A1 (es) Una muteina ob, una secuencia de adn, un vector de expresion una celula hospedadora procariota o de mamifero, un baculovirus recombinante, una celulahospedadora, un metodo para la produccion de una muteina ob, una composicion farmaceutica, el uso de una proteina ob para la preparacion de una composi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties